Apotex

83 articles about Apotex

• Apotex Receives FDA's Drug Shortage Assistance Award

  4/19/2023

  Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company's substantial efforts to resolve a shortage of varenicline tablets.

• One lot of APO-Amitriptyline recalled due to a nitrosamine impurity

  2/7/2023

  Apotex Inc. is recalling one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit.

• SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals

  9/28/2022

  An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc.

• Information Update - Apotex recalls additional Apo-Acyclovir tablets due to a nitrosamine impurity

  7/28/2022

  Apotex Inc. is recalling four additional lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity above or close to the acceptable level.

• First Generic Alternative to Eliquis Now Available in Canada

  6/20/2022

  Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis®. 

• Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis

  5/17/2022

  Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis.

• Advisory - Apotex recalls Apo-Acyclovir tablets due to a nitrosamine impurity

  4/28/2022

  Apotex Inc. is recalling certain lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity above the acceptable level.

• Information Update - Update: Certain lots of Elavil (amitriptyline) and APO-Amitriptyline recalled due to a nitrosamine impurity

  1/26/2022

  AA Pharma Inc. is recalling two lots of Elavil and Apotex Inc. is recalling one additional lot of APO-Amitriptyline 10 mg tablets due to the presence of NDMA, a nitrosamine impurity, above the acceptable limit.

• Voluntary Nationwide Recall: One Lot of Mirvala 28 (desogestrel and Ethinyl Estradiol Tablets, Usp) 0.150 Mg / 0.030 Mg Due to Possibility of One Placebo Pill in Place of An Active Pill

  9/30/2021

  Apotex Inc. is conducting a voluntary nationwide recall of one lot of Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) from wholesalers, distributors, retailers, pharmacies, and consumers.

• Canadian-Made Generic Option to Treat Multiple Myeloma Now Available

  9/1/2021

  Canada's largest pharmaceutical manufacturer, Apotex Inc., announced the Canadian launch of the generic version of Revlimid capsules, APO-lenalidomide for the treatment of multiple myeloma and Myelodysplastic syndrome.

• RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex

  7/22/2021

  RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.

• Government of Canada Awards Apotex Inc. a Significant Contract to Supply a Safety Net of Additional Dexamethasone in Canada

  4/15/2021

  As Canadians remain impacted by the spread of COVID-19, Apotex, Canada's largest pharmaceutical company has been awarded a contract with the Government of Canada to supply the Critical Drug Reserve of Dexamethasone tablets in response to the COVID-19 pandemic.

• 

  FDA Announces Five Companies Are Recalling Diabetes Drugs Over Carcinogen Concerns

  6/12/2020

  Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.

• Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

  1/13/2020

  Chiesi Farmaceutici S.p.A. and Apotex, Inc. announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox®.

• Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

  1/13/2020

  Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in the hematology and neurodegeneration therapeutic areas, announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox®.

• Apotex Releases New Supply of Tamoxifen Into Canadian Market

  12/5/2019

  Canada's leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market

• Information Update - Health Canada update on the tamoxifen shortage

  11/20/2019

  Health Canada is providing Canadians with an update on the supply of tamoxifen, a breast cancer drug, and information on efforts to resolve the national shortage as quickly as possible, recognizing the potentially significant impact that the shortage could have on patients.

• Information Update - Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled

  9/25/2019

  Health Canada recently informed Canadians that it is assessing the issue of an impurity called N-nitrosodimethylamine (NDMA) detected in some ranitidine drugs.

• CORRECTING and REPLACING Alcoholic Hepatitis Treatment Market Worth USD 570 Million, at 6% CAGR during 2019-2023 | Technavio

  7/16/2019

  According to Technavio Research Report "Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others), and geographic regions (North America, Europe, Asia, and ROW) is witnessed to grow by USD 570 million, at a CAGR of 6% from 2019 to 2023”.

• 

  $1.1 Billion in Lawsuits Filed Against Opioid Makers in Canada

  5/16/2019

  Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.